XORTX reveals positive results for Phase 2 trial of TMX-049
Category: #health  By Pankaj Singh  Date: 2019-09-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

XORTX reveals positive results for Phase 2 trial of TMX-049

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing on developing new drugs by means for novel clinical trials.

XORTX Therapeutics Inc., a biopharmaceutical firm that develops novel therapies to treat advanced kidney disease, recently shared promising results from the U.S. Placebo-Controlled, Randomized, Multicenter, Double-Blind, Phase 2 study to assess tolerability, safety and renal effects of TMX-049 in patients suffering from type 2 diabetic nephropathy.

According to reliable sources, the study intended to test if the inhibition of XO using the drug over a 12-week treatment program would offer an effective and safe therapeutic approach to reduce albuminuria and would decrease uric acid levels.

Commenting on the move, Dr. Allen Davidoff, President and CEO, XORTX Inc., said that the company feels TMX-049 is one of the best next-gen candidate xanthine oxidase inhibitors with a suitable combination of potent uric acid lowering ability and solid clinical safety record.

Moreover, the prospect of co-developing the drug for type 2 diabetic nephropathy alongside Teijin, while providing such significant results, significantly raise the probability of developing an advanced and novel drug to reverse and slow the progression of kidney disease in type 2 diabetic nephropathy patients.

However, earlier this year the company had acknowledged Dr. Petter Bjornstad and TODAY study team’s finding and study on youths going through Type 2 Diabetes (“T2D”). The findings revealed that high uric acid levels were normal in young subjects with T2DN (nephropathy) and that high SUA levels (serum uric acid) was an autonomous risk factor for development of kidney disease in this new and vulnerable group.

Additionally, the biopharma had highlighted an impactful finding by Pilemann-Lyberg et al. Reports cite that the results of this study of subjects with type 1 diabetic nephropathy progresses the crucial mass of seminal studies which reveal the detrimental effects of blood UA (uric acid) levels in the upper range of higher or normal patients suffering from diabetes.

Source Credit: http://www.xortx.com/2019/09/19/xortx-announces-positive-phase-2-results-in-type-2-diabetic-nephropathy-t2dn/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...